Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters

被引:8
|
作者
Popovici, Jean [1 ,2 ,3 ]
Tebben, Kieran [4 ]
Witkowski, Benoit [1 ,2 ,3 ]
Serre, David [4 ]
机构
[1] Inst Pasteur Cambodge, Malaria Mol Epidemiol Unit, Phnom Penh, Cambodia
[2] Inst Pasteur, Malaria Translat Res Unit, Paris, France
[3] Inst Pasteur Cambodge, Phnom Penh, Cambodia
[4] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA
关键词
MONOAMINE-OXIDASE; DRUG-METABOLISM; G6PD DEFICIENCY; MAO-A; MALARIA; ARTEMISININ; FALCIPARUM; POPULATION; RELAPSE; TAFENOQUINE;
D O I
10.1016/j.ijpddr.2020.12.004
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [21] Photon absorption and photon scattering-What we do not know and why it matters
    Pratt, R. H.
    RADIATION PHYSICS AND CHEMISTRY, 2014, 95 : 4 - 13
  • [22] Twenty years of pediatric diabetes surveillance: what do we know and why it matters
    Dabelea, Dana
    Sauder, Katherine A.
    Jensen, Elizabeth T.
    Mottl, Amy K.
    Huang, Alyssa
    Pihoker, Catherine
    Hamman, Richard F.
    Lawrence, Jean
    Dolan, Lawrence M.
    D' Agostino, Ralph, Jr.
    Wagenknecht, Lynne
    Mayer-Davis, Elizabeth J.
    Marcovina, Santica M.
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2021, 1495 (01) : 99 - 120
  • [23] Why we dont do, what we know?
    Hoeffken, K.
    Bamberg, M.
    Schlag, P. M.
    ONKOLOGE, 2009, 15 (01): : 84 - 84
  • [24] HOW DO WE KNOW WHAT WE KNOW AND WHY IS THAT IMPORTANT
    LAGOWSKI, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 205 : 268 - CHED
  • [25] Opioid overdose and the power of old myths: What we thought we knew, what we do know and why it matters
    Darke, Shane
    DRUG AND ALCOHOL REVIEW, 2014, 33 (02) : 109 - 114
  • [26] Failure to radical cure in Plasmodium vivax malaria
    Garcia, Julian
    Seijo, Agustin
    Benchetrit, Andres
    Couto, Esteban
    Echazarreta, Sofia
    Lloveras, Susana
    Orduna, Tomas
    REVISTA CHILENA DE INFECTOLOGIA, 2016, 33 (04): : 468 - 471
  • [27] Improving the Radical Cure of Plasmodium vivax Malaria
    Price, Ric N.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2014, 91 (01): : 3 - 4
  • [28] Environmental Analysis of Telework: What We Know, and What We Do Not Know and Why
    Horvath, Arpad
    PROCEEDINGS OF THE 2010 IEEE INTERNATIONAL SYMPOSIUM ON SUSTAINABLE SYSTEMS AND TECHNOLOGY (ISSST), 2010,
  • [29] Students' Perceptions of Testing Accommodations: What We Know, What We Need to Know, and Why It Matters
    Lovett, Benjamin
    Leja, Ashley
    JOURNAL OF APPLIED SCHOOL PSYCHOLOGY, 2013, 29 (01) : 72 - 89
  • [30] Epigenetics in Plasmodium: What Do We Really Know?
    Merrick, Catherine J.
    Duraisingh, Manoj T.
    EUKARYOTIC CELL, 2010, 9 (08) : 1150 - 1158